If the strategy of combined targeting of BRAFV600E signaling plus autophagy proves to be effective in BRAF-driven melanoma, this could open a therapeutic avenue for other BRAF-driven cancers, such as lung, colorectal, thyroid, and hairy cell leukemia. The gene discussed is BRAF; the disease is melanoma.